Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Meets Estimates

Nuvation Bio (NYSE:NUVB) announced its quarterly earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12), FiscalAI reports. The company had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI sales and market position strengthened: U.S. net product revenue rose 18% sequentially to $27.5 million, and the company said IBTROZI led the market in active patients and held more than 60% of first-line new patient starts.
• The overall ROS1 TKI market saw a roughly 15% decline in new patient starts during the quarter, while management noted that the pool of patients switching from older therapies is shrinking. Nuvation said future growth increasingly depends on first-line adoption, better testing, and converting patients to targeted treatment.
• Safusidenib advanced toward potential near-term data: The company cited encouraging long-term Phase II results and FDA Fast Track designation, and expects initial response data from two studies could emerge in 2027; randomized studies with progression-free survival endpoints are expected to take longer, potentially until 2029 or beyond.
• Nuvation reported $663.4 million in cash, cash equivalents, and marketable securities and said it believes it has sufficient capital to reach profitability. Management said IBTROZI’s quarterly revenue run rate now covers its launch-related expenses on a standalone basis, while operating expenses were $75.2 million for the quarter.

Nuvation Bio Stock Down 0.1%

NYSE:NUVB traded down $0.01 on Wednesday, hitting $4.68. 8,406,012 shares of the company’s stock traded hands, compared to its average volume of 5,497,224. The company has a market cap of $1.64 billion, a PE ratio of -10.64 and a beta of 1.73. Nuvation Bio has a 1 year low of $4.05 and a 1 year high of $9.75. The company has a current ratio of 8.37, a quick ratio of 8.14 and a debt-to-equity ratio of 0.96. The firm has a 50-day moving average price of $5.55 and a 200-day moving average price of $5.40.

Insider Buying and Selling

In related news, insider Gary Hattersley sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total value of $709,000.00. Following the completion of the sale, the insider owned 100,000 shares of the company’s stock, valued at approximately $709,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is owned by company insiders.

Analyst Ratings Changes

NUVB has been the topic of a number of recent research reports. Citizens Jmp reissued a “market outperform” rating and set a $10.00 price target on shares of Nuvation Bio in a research note on Wednesday, September 16th. HC Wainwright increased their price target on Nuvation Bio from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Cantor Fitzgerald began coverage on Nuvation Bio in a research note on Friday, August 21st. They issued an “overweight” rating for the company. Truist Financial raised their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.22.

About Nuvation Bio

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.